Comparative Pharmacology
Head-to-head clinical analysis: FORTOVASE versus TIVICAY PD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTOVASE versus TIVICAY PD.
FORTOVASE vs TIVICAY PD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Saquinavir is a protease inhibitor that binds to the active site of HIV-1 protease, blocking the cleavage of viral polyprotein precursors into functional proteins, resulting in the production of immature, non-infectious viral particles.
Tivicay PD (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing the integration of viral DNA into host chromosomal DNA, which is essential for viral replication.
1200 mg orally three times daily with food.
50 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in healthy subjects; prolonged to 2-5 hours in patients with hepatic impairment or when coadministered with ritonavir.
Terminal elimination half-life is approximately 12-15 hours in adults, supporting once-daily dosing.
Primarily hepatic metabolism via CYP3A4; 2% excreted unchanged in urine, 15% unchanged in feces; extensive biliary excretion of metabolites.
Primarily metabolized by UGT1A1 with minor CYP3A4; 53% of dose recovered in feces (30% as unchanged drug) and 31% in urine (18% as unchanged drug).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor